The Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes (SUSTAIN) phase III trials have shown that semaglutide has a strong glycated hemoglobin (HbA 1c )-lowering effect in patients with T2DM when injected subcutaneously once weekly [13,14,15,16,17,18,19]
Patients may be eligible for financial assistance programs as long as they meet a certain criteria
Dehydration from vomiting, diarrhea, fever, or poor fluid intake can also change risk
As an integrative supportive therapy alongside conventional care, glutathione can help protect healthy tissue, support detoxification, and improve overall resilience
Reliable methods to measure these compounds non-invasively in vivo are needed
Additionally, study design/quality (small single-center trials vs larger multicenter RCTs) can influence observed effects (Lee et al